Assenagon Asset Management S.A. Purchases 36,360 Shares of Keros Therapeutics, Inc. $KROS

Key Points

• Assenagon Asset Management S.A. increased its stake in Keros Therapeutics by 56.0% during the second quarter, acquiring an additional 36,360 shares, bringing its total holdings to 101,297 shares valued at $1.35 million.
• Several institutional investors have recently bought shares of Keros, with a reported 71.56% of the stock currently owned by hedge funds and other institutions.
• Keros Therapeutics has seen mixed analyst ratings, with a current average rating of "Moderate Buy" and a price target range between $15.00 and $30.00 following multiple price reductions.

Assenagon Asset Management S.A. grew its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 56.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,297 shares of the company's stock after acquiring an additional 36,360 shares during the period. Assenagon Asset Management S.A. owned 0.25% of Keros Therapeutics worth $1,352,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Corebridge Financial Inc. boosted its position in Keros Therapeutics by 6.4% during the 1st quarter. Corebridge Financial Inc. now owns 16,212 shares of the company's stock valued at $165,000 after acquiring an additional 972 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Keros Therapeutics by 7.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company's stock valued at $303,000 after acquiring an additional 1,386 shares in the last quarter. GAMMA Investing LLC boosted its position in Keros Therapeutics by 7,690.3% during the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock valued at $237,000 after acquiring an additional 2,384 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Keros Therapeutics in the first quarter valued at about $25,000. Finally, CWM LLC grew its stake in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after purchasing an additional 2,641 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

KROS has been the subject of several recent analyst reports. HC Wainwright reduced their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Wedbush reissued a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $30.00.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $16.05 on Friday. The firm has a market cap of $651.95 million, a price-to-earnings ratio of 51.78, a price-to-earnings-growth ratio of 2.04 and a beta of 1.06. The company has a 50 day moving average price of $14.94 and a 200-day moving average price of $13.79. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.Keros Therapeutics's revenue for the quarter was up 49002.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. On average, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.